Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Jia-Hao Jiang"'
Publikováno v:
Translational Oncology, Vol 50, Iss , Pp 102131- (2024)
Objectives: Four and a half LIM domain 2 protein (FHL2) was reported to regulate the progression of various cancers and this study aimed to clarify the intrinsic mechanism of FHL2 facilitating the progression of lung adenocarcinoma. Methods: In this
Externí odkaz:
https://doaj.org/article/a27bafb4dce545609f4a2c46d88bd533
Autor:
Jian Gao, Chun Jin, Jia-Hao Jiang, Jian-Yong Ding, Jie Deng, Shuai Wang, Hai-Kun Wang, Yong-Qiang Ao, Li-Cheng Zhang, Zong-wei Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Background Activating signal cointegrator 3 (ASCC3) has been identified as an oncogenic factor that impairs host immune defense. However, the underlying mechanisms of carcinogenesis and its impact on the antitumor immune response remain unclear. In t
Externí odkaz:
https://doaj.org/article/51cc22ca9d984c099e49f34c8b999dd2
Autor:
Yong-Qiang Ao, Jian Gao, Ling-Xian Zhang, Jie Deng, Shuai Wang, Miao Lin, Hai-Kun Wang, Jian-Yong Ding, Jia-Hao Jiang
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background The scavenger receptor CD36 was reported to be highly expressed on tumor-infiltrating CD8+ T cells, but the clinical role remains obscure. This study aims to explore the infiltration and clinical value of CD36+CD8+ T cells in NSCL
Externí odkaz:
https://doaj.org/article/22568d570f9747a89965020f0ebcf0d5
Autor:
Yong-Qiang Ao, Jian Gao, Shuai Wang, Jia-Hao Jiang, Jie Deng, Hai-Kun Wang, Bei Xu, Jian-Yong Ding
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-20 (2023)
Abstract Immunotherapy has emerged to play a rapidly expanding role in the treatment of cancers. Currently, many clinical trials of therapeutic agents are on ongoing with majority of immune checkpoint inhibitors (ICIs) especially programmed death rec
Externí odkaz:
https://doaj.org/article/28dc8c141a764b4aa228eaeeed87295b
Autor:
Jian Gao, Yong-Qiang Ao, Ling-Xian Zhang, Jie Deng, Shuai Wang, Hai-Kun Wang, Jia-Hao Jiang, Jian-Yong Ding
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-21 (2022)
Abstract Background Although success was achieved in the therapy for a minority of advanced lung adenocarcinoma (LUAD) patients, anti-programmed death 1 (PD1) resistance was found in most LUAD patients. Here, we aimed to uncover a potential role of e
Externí odkaz:
https://doaj.org/article/2141f83b42e34e2096e53a8538fd32c5
Autor:
Quan-Lin Li, Fang-Ming Gu, Zheng Wang, Jia-Hao Jiang, Li-Qing Yao, Chang-Jun Tan, Xiao-Yong Huang, Ai-Wu Ke, Zhi Dai, Jia Fan, Jian Zhou
Publikováno v:
PLoS ONE, Vol 7, Iss 3, p e33379 (2012)
Rapamycin is an attractive approach for the treatment and prevention of HCC recurrence after liver transplantation. However, the objective response rates of rapamycin achieved with single-agent therapy were modest, supporting that rapamycin resistanc
Externí odkaz:
https://doaj.org/article/a9a6939b55214a97a52ff75fd35cd41e
Autor:
Jia-Hao Jiang, 江家豪
102
This research is based on the Technology Acceptance Model to explore possible factors for both the seventh and ninth graders’ willingness to use On-line English E-learning conducted for ten weeks in Tan-show Junior High School in Taichung
This research is based on the Technology Acceptance Model to explore possible factors for both the seventh and ninth graders’ willingness to use On-line English E-learning conducted for ten weeks in Tan-show Junior High School in Taichung
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/05565651974960827498
Publikováno v:
JTCVS Techniques. 15:195-198
Autor:
Jia-Hao, Jiang, Jian, Gao, Chang-Yue, Chen, Yong-Qiang, Ao, Jing, Li, Yuan, Lu, Wang, Fang, Hai-Kun, Wang, Douglas Guedes, de Castro, Mariacarmela, Santarpia, Masaki, Hashimoto, Yun-Feng, Yuan, Jian-Yong, Ding
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: The ability of circulating tumor cells (CTCs) to identify lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) could improve pathological diagnosis and the selection of treatments for non-small cell lung cancer (NSCLC). Prev
Publikováno v:
Proceedings of the 28th Asia and South Pacific Design Automation Conference.